What are the recommended treatment steps for oro‑mandibular dyskinesia, including medication adjustment and pharmacologic options?

Treatment of Oro-Mandibular Dyskinesia

For patients with moderate to severe or disabling oro-mandibular dyskinesia (a form of tardive dyskinesia), treatment with a reversible VMAT2 inhibitor—specifically valbenazine or deutetrabenazine—is the recommended first-line pharmacologic therapy. 1

Initial Assessment and Medication Review

Before initiating specific treatment, immediately review and address the underlying cause:

• Identify and discontinue the causative dopamine receptor-blocking agent (DRBA) if clinically feasible, as oro-mandibular dyskinesia is most commonly drug-induced, particularly from antipsychotics, metoclopramide, or other DRBAs 2, 3, 4
• Document the duration of DRBA exposure, as tardive dyskinesia typically appears after at least 3 months of treatment and risk increases with cumulative dose and duration 1, 3, 4
• Assess severity using the Abnormal Involuntary Movement Scale (AIMS) to establish baseline measurements and guide treatment decisions 5
• Differentiate from drug-induced parkinsonism, which presents with bradykinesia and rigidity rather than involuntary facial movements, as anticholinergic treatment for parkinsonism will worsen tardive dyskinesia 4

Pharmacologic Treatment Algorithm

First-Line: VMAT2 Inhibitors

Valbenazine or deutetrabenazine are the only FDA-approved treatments for tardive dyskinesia and should be initiated for moderate to severe cases: 1, 3, 5

• Valbenazine: Start at 40 mg once daily, may increase to 80 mg once daily after one week based on tolerability and response 3
• Deutetrabenazine: Start at 6 mg twice daily, titrate weekly by 6 mg/day increments to optimal dose (typically 12-24 mg twice daily) 3

Key advantages of VMAT2 inhibitors:

• These agents deplete presynaptic dopamine without blocking dopamine receptors, so they do not cause or worsen tardive dyskinesia themselves 3
• Deutetrabenazine and valbenazine have superior pharmacokinetics compared to older tetrabenazine, allowing less frequent dosing and better tolerability 3
• Both medications have demonstrated efficacy in reducing involuntary orofacial movements in controlled trials 3, 5

Second-Line Options (if VMAT2 inhibitors unavailable or contraindicated)

Amantadine may be considered as an alternative, particularly if the patient has comorbid drug-induced parkinsonism, as it can address both conditions without worsening tardive dyskinesia 4

Clonazepam has been reported to provide benefit in some cases, though evidence is limited 3

Ginkgo biloba has shown some efficacy in small studies but should not replace VMAT2 inhibitors as first-line therapy 3

Critical Management Principles

What NOT to Do

Avoid anticholinergic medications (benztropine, diphenhydramine) for oro-mandibular dyskinesia, as these agents can worsen tardive dyskinesia despite being appropriate for acute dystonic reactions 1, 2, 4

Do not use the causative antipsychotic to suppress symptoms, as this masks the underlying disease process without treating it and may worsen long-term outcomes 2

Do not continue metoclopramide or other DRBAs beyond 12 weeks unless absolutely necessary, as the risk of developing tardive dyskinesia increases substantially with prolonged exposure 2

If Antipsychotic Cannot Be Discontinued

When the underlying psychiatric condition requires continued antipsychotic therapy:

• Switch to quetiapine, clozapine, or pimavanserin, which have the lowest risk of causing or worsening movement disorders 6
• Initiate VMAT2 inhibitor therapy concurrently to treat the existing tardive dyskinesia 1, 3
• Monitor closely with AIMS assessments every 3-6 months to detect progression 5

Prognosis and Monitoring

Tardive dyskinesia may be irreversible, particularly with longer duration of symptoms before treatment, though some patients experience partial or complete remission after discontinuing the causative agent 2, 3

The likelihood of permanence increases with:

• Duration of DRBA exposure 2, 3
• Total cumulative dose of DRBAs 1, 2
• Older age, female sex, and diabetes mellitus 1
• Delay in recognition and treatment 5

Monitor treatment response using AIMS scores at baseline, 4-8 weeks, and every 3 months thereafter to objectively assess improvement and guide dose adjustments 5

Special Considerations

For patients with acute dystonic reactions (torticollis, oculogyric crisis, laryngospasm) rather than tardive dyskinesia, immediate treatment with intramuscular diphenhydramine 50 mg or benztropine 1-2 mg is appropriate, as this represents a different pathophysiology requiring different management 2

Distinguish oro-mandibular dyskinesia from parkinsonian symptoms (mask-like facies, bradykinesia), which typically appear within 6 months of starting DRBAs and may respond to dose reduction or anticholinergics 2